Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drop symbols : SRNE save search
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
Published: 2022-03-02 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 sars-cov-2 drop antibody infection infections
Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK
Published: 2022-01-19 (Crawled : 17:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
phase 2 trial drop enroll
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
Published: 2021-07-21 (Crawled : 14:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
phase 2 drop trial authorized
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.37%
H: 2.41%
C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.